• The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO
• These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in C. difficile Infection (CDI)
  • As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.